Skip to main content

Table 3 Use of cardioprotective agents and mortality

From: Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center

Drug class Total (n = 424) Mortality (%) p-value
Beta-Blockers Yes (n = 252) 126 (50%) 0.013
No (n = 172) 65 (37.8%)
ACE Inhibitors Yes (n = 146) 69 (47.3%) 0.507
No (n = 278) 122 (43.9%)
Angiotensin Receptor Blockers Yes (n = 55) 26 (47.3%) 0.722
No (n = 369) 165 (44.7%)
Statins Yes (n = 164) 75 (45.7%) 0.822
No (n = 260) 116 (44.6%)
  1. ACE angiotensin converting enzyme